

## Pharmacy and Therapeutics Advisory Committee Recommendations

September 21, 2006 Meeting

This chart provides a summary of the final PDL selections that were made by the Secretary for Health and Family Services as a result of the Pharmacy and Therapeutics Advisory Committee meeting of September 21, 2006.

	<b>Description of Recommendation</b>	<b>Final PDL Decision</b>
#1	<p><b>Serotonin (5-HT<sub>1</sub>) Receptor Agonists - Triptans</b></p> <ol style="list-style-type: none"> <li>1. All triptans and all dosage forms are considered clinically equivalent in efficacy and safety.</li> <li>2. DMS to select at least 3 branded oral agents with one of those branded oral triptans to include an alternative delivery system to use as preferred based on economic evaluation.</li> <li>3. Agents not selected as preferred based on economic evaluation will require PA.</li> <li>4. Continue monthly quantity limits per manufacturer guidelines with PA required for additional medication.</li> <li>5. Require PA for duplicate therapy/concurrent use of triptans by different routes.</li> <li>6. Require failure of all preferred agents before PA approval of a nonpreferred agent.</li> <li>7. Implement a continuation of therapy clause which allows patients currently on medications not selected as preferred to continue to receive their medication.</li> <li>8. For any new chemical entity in the triptan class, require a PA until reviewed by the P&amp;T Advisory Committee.</li> </ol>	<p>Recommendations Approved</p> <p><b><u>PDL Selections</u></b>  <b>IMITREX</b>  <b>MAXALT</b>  <b>ZOMIG</b></p>
#2	<p><b>Anti-Viral Agents, Herpes</b></p> <ol style="list-style-type: none"> <li>1. The antiviral agents for herpes are considered clinically equivalent in efficacy and safety.</li> <li>2. DMS to select acyclovir and at least one branded agent as preferred based on economic evaluation.</li> <li>3. Agents not selected as preferred based on economic evaluation will require PA.</li> <li>4. For any new chemical entity in the class, require a PA until reviewed by the P&amp;T Advisory Committee.</li> </ol>	<p>Recommendations Approved</p> <p><b><u>PDL Selections</u></b>  <b>ACYCLOVIR</b>  <b>FAMVIR</b>  <b>VALTREX</b></p>